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Introduction   
Multiple sclerosis (MS) is an autoimmune, inflammatory demyelinating condition.  T helper cells and antigen presenting 
cells ultimately coordinate the production of inflammatory cytokines and chemokines within the central nervous system 
(CNS) parenchyma, leading to recruitment of pro-inflammatory mediators, and finally destruction of the myelin sheath 
and axons (1). Axonal loss presents a key pathophysiological mechanism of progressive disease; and progressive axonal 
damage is likely to be due to a combination of persistent myelin and oligodendrocyte loss (causing loss or trophic 
support and sustained demyelination-induced conduction block) and continuous exposure to injurious agents (2).  
MS affects some 25 million people worldwide. More than 80% of patients ultimately develop progressive disability, 
despite commencing with a relapsing remitting course, with a median time to progression of 15 years (3). 10-20% of 
patients have a primary progressive (PPMS) course (4). The costs of MS increase dramatically with increasing disability 
and impairment (5). In stark contrast to relapsing-remitting disease, for which there is a wide and still increasing choice 
of drugs, there are no conventional treatments that offer significant efficacy in preventing or reversing  the accumulation 
of disability (6). As with so many other neurodegenerative conditions, cell therapy for MS appears to be a highly 
attractive therapeutic option and, over the last few decades, there has been rapid translation from in vitro and in vivo 
experimental studies to safety and feasibility trials across the world. Nonetheless, the challenges facing the development 
of cell therapy for the treatment of MS remain daunting.  
MS is generally accepted to be an autoimmune disease, with oligodendrocytes and the myelin sheaths they synthesise 
and support representing the primary target of this autoimmunity, although much remains extremely poorly understood. 
Not least, we do not know what triggers the disease. We also do not know why inflammation occurs in patches in the 
CNS, rather than diffusely, nor why some areas of the brain and spinal cord are more susceptible than others. And 
perhaps least of all do we understand how this patchy inflammatory demyelination relates to the progressive neuronal 
and axon loss that underlies the progressive disability occurring in most patients with MS, a phase of the disease which 
has the pace and features far more suggestive of a degenerative than an inflammatory condition. These areas of 
significant uncertainty clearly impede the development of rational therapies, cell-based and otherwise. Another 
challenge is the lack of clinically relevant experimental models of disease – experimental autoimmune 
encephalomyelitis (EAE) models are usually characterised by relapses with rapid recovery of inflammatory damage but 
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no progressive neurodegenerative phase and models of focal, chemically-induced demyelination demonstrate little or 
no inflammatory toxicity. Assessing neuroprotective therapies in MS also presents a continuing major challenge because 
of the variability of disease features and course of the disease, combined with the insensitivity of generic clinical 
outcome measures (7).  
The complexity of the disease helps to explain the complexity of current approaches to cell therapy in MS. There are 
three quite different types of cell therapy actively being explored, variably aiming to exploit the therapeutic properties 
of different stem cells to achieve inhibition of the immune pathogenesis of disease, neuroprotection and to promote 
repair. This review will present an overview of where we are now with cell therapy in MS.  
 
1. Approaches to cell therapy in MS 
 
Replacing oligodendrocytes 
In 1977, it was shown that exogenous myelinating cells injected into demyelinated lesions in the rodent CNS achieved 
successful remyelination (8). Transplantation of myelin forming cells, either directly into MRI-disclosed lesions, or with 
the intention of their dissemination through the entire neuro-axis, has been a major aim ever since (9). In a variety of 
experimental paradigms, many types of transplanted cells have successfully remyelinated acute focal demyelinated 
lesions in the adult CNS (10).  
Embryonic stem cells were until recently considered the best putative candidates for such an approach. However, it is 
now clear that human dermal fibroblasts, and other somatic cells, can be reprogrammed to pluripotency via retroviral 
transduction (induced pluripotent stem cells or iPSCs); and more recently the same has been achieved by chemical or 
pharmacological approaches. MS-patient derived iPSCs can differentiate into oligodendrocytes (as well as astrocytes 
and neurons) with normal karyotypes, and these can then achieve myelination in vivo in the shiverer mouse (11). IPSCs 
are probably now the more favoured cell vehicle for oligodendrocyte replacement, although the protocol for induction 
is inefficient, and concerns remain about genomic stability and the tumour risk associated with using these cells 
therapeutically. (12).  
In addition, however, there are conceptual difficulties with this approach. Both oligodendrocyte progenitors and neural 
precursors are in fact present in significant numbers in MS lesions, yet they are unable to regenerate myelin, perhaps as 
they are unable to differentiate, and show arrested development (3). It is not clear that adding more cells would help 
under these circumstances. Also, while inflammatory demyelinating lesions cause relapse-related neurological 
dysfunction, their direct relationship to chronic progressive disability is unclear and uncertain; neither lesion load, lesion 
site, nor the number of relapses correlate well with chronic disability (3). It has therefore become difficult to see how 
patients with secondary and primary  progressive disease might benefit from directly injecting oligodendrocyte 
progenitors into MRI-disclosed lesions (3) – though a case might still be made in occasional patients with very large 
lesions causing relapse-related symptoms, who develop disability as a direct effect of significantly incomplete 
spontaneous remyelination.  
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What is undeniable however is that the intensive study of the molecular and cellular neurobiology of myelin repair 
stimulated by and originally directed towards oligodendrocyte replacement therapy has yielded invaluable new 
knowledge concerning remyelination, knowledge which has directly lead to molecular candidates for promoting myelin 
repair – either small molecules as conventional pharmacological agents, or monoclonal antibodies, several of which are 
now undergoing early phase clinical trials (13).  
 
Autologous haematopoietic stem cell transplantation  
Autologous haematopoietic stem cell transplantation (AHSCT) is a promising treatment for MS, perhaps particularly 
for those who have not responded to conventional immune therapies (14).  AHSCT is a well-established procedure for 
the treatment of poor prognosis haematological malignancies, and in the last 20 years it has been explored to treat 
patients with severe autoimmune diseases who were deteriorating despite receiving standard treatments (15). The 
rationale for this approach is that ablation of the aberrant immune system followed by reconstitution of a ‘new’ immune 
system from haematopoietic stem cells should substantially alter the characteristics of the T-cell responses, and other 
immune reactivities, and so potentially improve the clinical course of autoimmunity, including MS (16). Following early 
reports such as that from Fassas et al (17), MS has become one of the most common autoimmune diseases to be treated 
with AHSCT (18). In 1997, the Autoimmune Diseases Working Directive (ADWP) of the EBMT set guidelines for 
application of AHSCT to autoimmune disease, and advised that all cases treated should be registered within the 
European Group for Blood and Marrow Transplantation (EBMT) database (19). Over 2000 patients with an autoimmune 
disorder have now been reported to the Registry of the EBMT as having been so treated, of whom more than 800 have 
MS.  
The source of stem cells is commonly bone marrow, cord blood or peripheral blood. Peripheral blood stem cells (PBSC) 
contain more progenitor cells and mature lymphocytes than bone marrow. In addition, with PBSC, there is the ease of 
collection, since bone marrow has to be collected by a general anaesthetic. However, since the numbers of PBSC are 
small, they must first be mobilised from the bone marrow using cyclophosphamide (Cy) or growth factors such as 
granulocyte colony stimulating factor (G-CSF). The combination of Cy and G-CSF is generally preferred as Cy reduces 
the potential risk of MS exacerbation in response of G-CSF and the inclusion of Cy in the mobilisation regime decreases 
the number of T cells in the apheresis collection (20).  
Once harvested, haematopoietic stem cells (HSCs) can be manipulated (termed in vitro purging) by either CD34+ 
positive selection for lymphocyte depletion and/or directly purged with anti-lymphocyte antibodies (such as with 
CAMPATH 1H or cytotoxic agents) (21). HSCs carry the CD34 and Thy-1 markers and these surface markers are 
usually used to isolate cells including early progenitors (21).   
Having collected and prepared HSCs for transfusion, the patient’s own immune system must be ablated, or at least 
suppressed sufficiently to allow the infused HSCs to regenerate the immune system in preference to the ‘original’ 
immune system re-asserting itself. This process is ‘conditioning’; different conditioning regimens can be administered 
before the infusion of CD34+ autologous cells (22), and the patient is usually admitted for conditioning. Common 
regimes utilised vary in intensity; examples are listed below:-  
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• high intensity regimes include total body irradiation (TBI) or high dose busulfan  
• low intensity conditioning regimens utilise cyclophosphamide alone, melphalan alone, or fludarabine-based 
regimens 
• intermediate intensity regimens include other combinations such as BEAM, or anti-thymocyte globulin (ATG) 
and cyclophosphamide (23)  
The combined carmustine (BiCNU®), Etoposide, cytarabine (AraC) and Melphalan (BEAM) conditioning regime is 
considered the most effective (16). The risk of transplant-related mortality (TRM) in HSCT, defined as deaths occurring 
in the first 100 days (24) has decreased from 2001, according to EBMT, likely due at least in part to the avoidance of 
aggressive regimes which resulted in toxicity, such as the use of busulfan (20).     
Finally, following the conditioning stage, at least 2x106 CD34+ positive cells/kg of body weight is required for 
haematological reconstitution (21). Haematological recovery requires a mean of 12 days to reach a neutrophil count 
>500/µl, and 10 days to reach a platelet count of >20x109 (22).  
HSCT also has been shown to normalise microRNA and gene expression and improve the immune-regulatory network 
(25). Using microarray DNA-chip technology, AHSCT was found to alter gene expression of peripheral CD4+ and 
CD8+ T-cell subsets – clusters of reconstituted CD8+ T cells of MS patients two years after transplantation were more 
similar to healthy controls. There were more extensive changes in the expression of genes involved in the effector 
immune response (26). AHSCT induces profound modifications in the immune-regulatory compartment, such as a 
transient increase in regulatory FoxP3+ T-cells (22). In MS, AHSCT renews the CD4+ repertoire, blunts the 
encephalitogenic effector response by reducing Tc17 and Th17 peripheral blood T-cells, impairs antigen presentation, 
and increases the numbers of immune-regulatory cells (22).   
Conversely, autopsy material from five MS patients who received AHSCT showed that there was ongoing evidence of 
active demyelination, while the inflammatory infiltrate within the lesions showed predominantly CD8+ cytotoxic T 
cells, with high numbers of acutely damaged axons. This implies that despite AHSCT (and the accompanying 
immunosuppression), there is ongoing disease activity – arguably also reflected in patients exhibiting continued disease 
progression and/or MRI activity in AHSCT trials (27). AHSCT has also been associated with rapid brain volume loss 
in the months subsequent to treatment, which then declines after two years. The initial loss may be due to pre-transplant 
disease activity or result of the intense immune-ablative conditioning procedure (28).  
Nonetheless, it seems clear that AHSCT can reduce clinical relapse activity dramatically, with a potency comparable 
(or, it has been claimed, superior) to the current most powerful licensed therapies, alemtuzumab and natalizumab. Its 
morbidity and mortality may, however, be greater, and so the place of AHSCT in the overall treatment paradigm of 
relapsing remitting MS remains to be defined. Comparative studies are required. 
 
Mesenchymal stromal cells (MSCs) and related cells 
As well as haematopoietic stem cells, bone marrow contains other cell types with stem cell-like properties, including 
mesenchymal stromal cells. Many stem cell researchers concentrate on these cells, not in the least because of their 
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properties in promoting cell repair through multiple mechanisms, combined with immune-modulating and immune-
suppressive actions. MSCs can stimulate local proliferation of endogenous neural precursors, secrete various trophic 
factors, and protective antioxidants such as superoxide dismustase-3, reduce gliotic scar formation and promote CNS 
neurite outgrowth and remodelling (3, 29, 30).  
MSCs are a rare and heterogeneous population of cells, which are relatively easy to extract and expand from a number 
of tissues in the body including bone marrow. They were first described by Friedenstein et al in 1968 (31). No single 
marker or even combination of markers specifically identifies MSCs. Criteria proposed by the Mesenchymal and Tissue 
Stem Cell Committee of the International Society for Cellular Therapy include plastic-adherence during in vitro 
expansion, absence of hematopoietic surface markers (such as CD45, CD34), presence of CD73, CD90, and CD105 
surface markers, and ability to undergo in vitro differentiation into adipocytes, chondroblasts and osteoblasts (32). Their 
normal function is to support HSCs within the bone marrow niche, but they also have a systemic role, following release 
into the circulation, in maintaining vascular and immunological homeostasis and facilitating tissue repair (33). They 
have a selective ability to home to sites of tissue damage or inflammation, a process mediated by chemokine receptors 
and other adhesion molecules (1). MSCs have a number of immuno-modulatory properties, such as suppression of T 
cells leading to a concomitant increase in the Th2 cytokine IL4 (34). MSCs can promote self-tolerance by inhibiting the 
ability of dendritic cells to become antigen presenting cells (12).  
MSCs also have a number of neuroprotective properties. They promote oligodendrogliogenesis, neural survival and 
neurite outgrowth, and protect neurons against oxidative stress, partly through the secretion of neurotrophins such as 
brain derived neurotrophic factor and nerve growth factor (29, 35). Rather remarkably, they can also protect tissue by 
directly transferring mitochondria to vulnerable cells through a process involving membrane fusion (36). They can fuse 
with cells to promote target cell survival (37).  
MSCs therefore offer potential therapeutic benefit in MS by restricting inflammation, protecting axons, neurons and 
glia, and promoting remyelination (38). Systemic transplantation of autologous or allogeneic MSCs in relapsing-
remitting or progressive models of EAE showed a decrease in T and B cell responses, accompanied by clinical and 
histological improvements, reducing the number of inflammatory lesions, reducing axonal loss and preserving myelin 
structure (39, 40). Immunological analysis revealed an increase in the proportion of CD4+CD25+ regulatory T cells, a 
decrease in the proliferative responses of lymphocytes, and the expression of CD40+, CD83+, CD86+ and HLA-DR on 
myeloid dendritic cells at 24 hours after MSC transplantation (41). 
There are, however, a number of theoretic risks in the application of MSCs. Close monitoring during infusion is 
necessary because of potential toxicity related to an allergic reaction to foetal bovine serum (FBS) in the culture medium, 
dimethyl sulfoxide (DMSO) in the freezing medium, and the risk of pulmonary embolic phenomena. Utilisation of FBS 
raises several issues: for example, anti-FBS antibodies might react with FBS antigens adherent to MSCs, leading to 
rejection or to infusion-related allergic reactions. FBS could also theoretically transmit infection, including zoonoses 
such as bovine spongiform encephalopathy (42, 43). Therefore, the development of serum-free culture methods is a 
priority. Culture-expanded MSCs can trigger a so-named ‘Instant Blood-Mediated Inflammatory Reaction’ (IBMIR), 
mediated by the innate immune system (33, 43, 44). A further infection risk comes with ex-vivo expansion; which also 
may enhance the possibility of ectopic tissue formation. When culture-expanded MSCs were administered 
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intraventricularly, they migrated into the brain parenchyma and formed cellular masses with focal inflammation. Local 
tissue damage and collagen-fibronectin deposition were observed (45). Cancer related to malignant transformation of 
culture-expanded MSCs or permissive effects of immunosuppression is also a theoretical concern (33). In vivo, MSC 
transplantation could conceivably have pro- or anti-inflammatory effects in MS (46): suppressing the ‘wrong’ 
component of the immune system, or precipitating (perhaps by some allergy-related mechanism) a general increase in 
immune activation, could conceivably exacerbate relapsing-remitting MS. One recent report described a patient with 
MS who developed acute disseminated encephalomyelitis-like illness six hours after the third of three monthly 
intrathecal injections of autologous MSCs (47).  
The optimal route and dose of MSC administration is still debated. If we assume that the cells are required to access the 
CNS to be clinically effective, a drawback of intravenous administration of MSCs is that cells will become trapped in 
the lungs, or will home to lymph nodes and other tissues, reducing the number of cells available to migrate to the CNS 
(41). An intrathecal approach for cell-based therapies in neurological disease such as MS, in which areas of tissue 
damage are widespread throughout the neuro-axis, may increase the likelihood of migration of the injected cells to the 
closer proximity of areas of CNS damage. The injected cells may circulate with the flow of cerebrospinal fluid and so 
gain a better chance of reaching affected areas (41); but intrathecal delivery of MSCs is, however, complicated by a 
common meningeal reaction. Very little evidence is available on formal dosing of MSCs for transplantation; a commonly 
used dosage is 1-2x106 cells per kg (33).  
The extent of engraftment and duration of survival of donor MSCs after transplantation in humans is largely unknown. 
Autopsies of 18 patients who received HLA-mismatched MSCs for complications of HSCT, showed little evidence of 
MSC DNA in donor tissue (48). Engraftment and magnitude of therapeutic response correlate poorly, and a paracrine 
effect with persistent therapeutic benefit that is not dependent on surviving implanted cells is postulated for some 
treatment effects – the so-called “hit and run” mechanism of action. While sustained beyond the duration of cell 
‘residence’, such effects are likely ultimately to subside, and so repeated administration may be required. Harris et al 
found that multiple administration of MSCs in a rodent inflammatory demyelination model was more likely to help 
arrest progression (49). The risk of sensitisation would, however, likely confine such an approach to autologous MSCs 
(33) – repeated administration of allogeneic MSCs does generate problematic immune reactivity (50). The possibility 
that recurrent administration of autologous MSCs may be required raises further practical questions – would these be 
achieved by repeated harvests, or perhaps through expansion with cryopreservation? Before culture-expanded MSCs 
can be seen as an “off-the-shelf” product (33),  comprehensive certification of the donor would be required to rule out 
infection and cancer. Regulatory hurdles would be more difficult. 
We do not know whether autologous or allogenic MSCs might be more effective. There is a theoretical concern that 
autologous cells from a patient with an inflammatory and degenerative disorder may have defective immunomodulatory, 
tissue protective or reparative capabilities (33). This possibility has been explored by Mallam et al (51) and by Mazzanti 
et al (52), where MSCs from patients with secondary progressive MS (SPMS) and relapsing remitting MS (RRMS) 
were found to be similar to controls in a number of parameters. However, Mazzanti et al did find that MS patient MSCs 
had significantly greater lipopolysaccharide-stimulated IP10 production compared to healthy controls, while Mallam et 
al had only explored a relatively small number of patients with MS. In an interesting study, MSC gene expression 
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profiles and also function were compared between control patients and individuals with MS both before and then after 
autologous HSCT. Pre-HSCT, MSCs had distinct transcriptional profiles compared to controls, including 
downregulation of TGFB1 and HGF genes, and reduced secretion of IL-10 and TGF-B. Six months after transplantation, 
the transcriptional profile remained similar to pre-transplant AHSCT; post-transplantation MS patient MSCs were closer 
to pre-AHSCT samples than to healthy MSCs. These findings therefore showed that MS-MSCs exhibited phenotypic 
changes, distinct transcriptional profiles and functional defects in immunomodulatory and immunosuppressive activity, 
not ‘corrected’ by HSCT, implying that allogeneic bone marrow MSCs might be better as a putative treatment cell type 
(53). The question, however, is not definitively resolved, and studies of the phenotype and function of MSCs isolated 
from MS patients, including those involved in ongoing and planned treatment trials, will be important to explore this 
issue further (33).   
Human bone marrow derived MSCs can be safely extracted, expanded in vitro and, despite the theoretical risk, do not 
seem to be susceptible to malignant transformation; thus they appear to be suitable for clinical application (54). To date 
the largest studies of therapeutic MSC transplantation have been in haematological malignancy, breast cancer,  
ischaemic heart disease, and in graft-versus-host disease (55). With no induction or conditioning, trials involving MSCs 
have no treatment-related mortality, and the side-effect profile includes mostly transient and self-limiting adverse events. 
This likely safety and the beneficial effects of MSCs in other disorders in these trials (though variable), combined with 
the experimental indications of likely benefit in whole animal or cellular models have provided justification for clinical 
testing in MS. Initially, clinical trials focused on safety and proof-of-concept. Connick et al recruited ten participants 
with MS, and additional controls, in 2008-2009, and successfully isolated, expanded and characterised MSCs in vitro, 
which then lead to an open label safety and feasibility trial (7). An improvement in visual function was reported, as 
indeed had earlier been suggested in comparable studies by Yamout et al (56). Other similarly small trials have reported 
stabilisation of progression or a modest improvement in EDSS (Expanded Disability Status Score) with MSC infusion 
(see table 1). An international multi-centre trial, MESEMS (mesenchymal stem cells for multiple sclerosis) is currently 
ongoing (57). 
At the same time, refinements of the MSC approach are already under experimental consideration: for example, priming 
cells in various ways in culture before infusion, or genetically modifying MSCs, in order putatively to improve aspects 
of their function including survival, neuroprotective or restorative function, or homing to specific target tissues. One 
example would be to increase the expression of hepatocyte growth factor, which has been implicated in the efficacy of 
MSCs in EAE (48).  
Related approaches 
MSCs can be obtained from tissues other than the bone marrow. ‘PDA-001’ is a preparation of mesenchymal-like cells 
derived from full-term human placenta tissue. PDA-001 caused a dose-dependent protection from EAE induction, and 
in established EAE, a reduction of disease progression and severity (58). PDA-001 has now also been investigated in a 
multi-centre, randomised, double-blinded trial in patients with RRMS and SPMS (59), the first therapeutic trial of its 
kind to investigate the human placenta as a source for therapeutic stem cells (Table 1). In this study, 81% of patients 
were taking at least one other licensed MS medication concomitantly, and so identifying treatment effect was 
complicated, but PDA-001 administration in patients with MS appeared to be both safe and feasible. PDA-001 may 
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have significant benefits as an alternative source of cells: the full-term placenta is a safe and plentiful source of non-
embryonic cells; and production scalability is also feasible (59). 
Within bone marrow, a number of stem cell sub-populations are present in addition to haematopoietic stem cells and 
MSCs. These include multipotent adult progenitor cells, and STRO-1-positive cells, both of which (and also including 
HSCs) have been reported to have reparative and neuroprotective properties. It is suggested that these various 
populations may contribute synergistically to promote tissue repair (3). Certainly, no one sub-population has been shown 
to be more effective than other sub-populations, and some studies report that the unselected (and unexpanded) mixed 
bone marrow mononuclear cell populations containing all these cell types and others may be more effective 
therapeutically than purified and expanded MSCs. The approach of utilising a filtered preparation of whole bone 
marrow, aiming to maximise the likelihood of including any and all sub-populations of potentially useful BM-resident 
stem cells, has been explored clinically in a number of disorders with apparent benefit. We have studied this approach 
in a small number of MS patients in an uncontrolled phase I trial (60). The data support the safety and feasibility of the 
approach as well as raising the possibility of a treatment effect. This therapeutic approach, were it to prove beneficial in 
larger controlled studies (61), would carry the additional advantage of practical ease of adoption and application in non-
specialist units, lacking as it does in the cell expansion-related requirement for a Good Manufacturing Practice (GMP) 
cell culture and selection facility.  
Neural stem or precursor cells (NPCs) also have neuroprotective properties, as shown in EAE models, where NPC 
transplantation can lead to significant reduction of the clinical severity of the disease and reduction of pathological 
parameters of inflammation (62). Using a viral model of demyelinating disease, intra-spinal transplantation of human 
embryonic stem cell-derived NPCs resulted in sustained clinical recovery (63).  Clinical application of these cells in MS 
is being planned (61).  
 
2: Efficacy and safety of trials in cell therapy 
Table 1 shows an overview of reported trials of different types of cell therapy in MS. The great majority of these have 
explored AHSCT, with a mixed cohort of patients with MS, including those with RRMS or SPMS, so that distinguishing 
between efficacy for RRMS and for SPMS can be challenging. Still, given the likely substantial differences in 
mechanisms of tissue damage, and in clinical impact, it is worth attempting to explore the clinical trial data specifically 
for distinct effects on relapse activity and on progressive disease.  
 
Efficacy – relapse suppression 
Individual early case reports showed that treating patients with highly active RRMS using AHSCT was beneficial, 
particularly in cases with highly active inflammatory disease. These patients showed significant improvement in EDSS, 
and suppression of relapses over a period of 12-24 months, without any additional disease-modifying therapies (DMT). 
MRI findings also suggested no subclinical disease activity. These examples demonstrated the therapeutic potential of 
AHSCT (64, 65). Another case report explored the administration of Cy and non-myeloablative AHSCT (and ATG) in 
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a patient with malignant type MS, with a pre-treatment EDSS of 8.0, which improved to 6.5 after 1 year, with no new 
lesions demonstrated on MRI (66), again suggesting that AHSCT can be effective and safe even during periods of 
extreme inflammation and disability, with a lasting therapeutic effect. Similar dramatic improvements in EDSS with 
suppression of relapse activity have been noted in other patients with “malignant” RRMS (67). Recurrence of relapse 
after autologous HSCT can occur, however, and has been attributed both to the pre-transplantation conditioning regimen 
(68), with failure to eliminate all anti-myelin reactive cells, and also to the T lymphocytes that may be present among 
the autologous graft (69). 
Following these earlier reports, Burt et al (70), utilising a non-myeloablative AHSCT approach in a relatively large 
study (123 patients with relapsing-remitting MS, and 28 with secondary-progressive disease), showed impressive 
outcomes, with 80% of patients showing relapse-free survival at 4 years. The adverse event profile was good, with a 
few cases of ITP and autoimmune thyroid disorder, and no transplant related mortality (TRM). It is worth noting that 
during the conditioning period, alemtuzumab was utilised, and since this immunomodulatory drug is highly effective in 
RRMS, it is difficult to isolate the benefit of AHSCT on its own.  
Using a more aggressive immune-ablative approach, Atkins et al (71) recently reported dramatic relapse activity effects 
- with not a single relapse occurring in 24 patients post-AHSCT, and not a single gadolinium-enhancing lesion on 
repeated post-transplant MRI scanning. However, there were a number of adverse events, including hepatic necrosis 
(resulting in death), an ITU admission involving sinusoid obstruction syndrome, thyroid dysfunction, and febrile events 
including positive cultures. 
 
Efficacy – preventing disability progression 
Here, efficacy is often expressed as progression-free survival (PFS), defined as the absence of a confirmed increase in 
EDSS by at least 1 point. In studies with a follow-up of at least 2 years, progression-free survival ranged from 36% to 
100%, and only a minority of patients showed an improvement in EDSS (22). There are a number of complications in 
assessing the clinical significance of such studies. First, disability progression in relatively short term studies in MS is 
notoriously unreliable, partly because progression is often very slow in MS, and partly because disability changes in 
relatively short term studies may substantially reflect improvement from pre-HSCT relapses rather than implying 
changes in underlying disease progression. Thus in Burman et al’s study, where improvement was reported, the majority 
of the improvement took place during the first year, with some additional improvement in the second year, but no further 
improvement subsequently (72). In the assessment of effects on disability progression, most authorities lend more 
weight to longer term studies, such as Fassas et al (73): here, progression-free survival was notably lower than in those 
studies with shorter term follow-ups.  
Secondly, often impressive and sustained suppression of Gd+ lesions or overall volume of T2 lesion load reduction on 
MRI can been noted post-AHSCT (24, 74). Perhaps unsurprisingly, however, these positive MRI findings do not 
necessarily imply, and have not been accompanied by comparable improvements in clinical disability in patients. 
Suppression of MRI enhancement in trials using myeloablative regimens in patients with progressive disease is difficult 
to interpret, as in the progressive phase of MS, MRI enhancement normally decreases spontaneously (75). 
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And thirdly, the relationship between relapses and disease duration prior to treatment should be considered; relapse 
frequency decreases with disease duration in MS, and so the results of studies assessing disability progression are less 
likely to be ‘contaminated’ by relapses (and recovery) if patients with more chronic disease are targeted. Burt et al found 
that the EDSS score did not improve in patients with disease duration longer than 10 years (70) (or more generally in 
patients with SPMS). A related, confusing influence of relapses may explain the results of studies showing that patients 
with SPMS have a higher probability of remaining ‘progression-free’ than those with PPMS (68).  
In a retrospective survey of the EBMT database, the advantages of treating early, in the inflammatory phase of the 
disease are discussed: younger patients, transplanted within 5 years from diagnosis, showed significantly better 
progression-free survival (19). Similarly, Krasulova et al commented that patients with relapsing MS, disease duration 
<5 years and age <35 years old have a more favourable outcome from AHSCT (76). MS patients with long-lasting 
disability have been shown to be poor responders to HSCT, presumably due to the likely irreversibility of chronic lesions 
(69).  
In Burt et al’s study exploring less intense immunosuppression (68), 87% of patients were found to have progression-
free survival. It is worth mentioning that the mean age of patients in this trial is lower, and mostly RRMS patients were 
recruited. The trial also had a relatively short follow-up period (median follow-up 2 years). Even with more intense 
myeloablation, Atkins reported 69.6% of patients to have disease-free survival at 3 years (71). 
 
Safety 
The majority of trials have explored conditioning regimes utilising BEAM therapy – carmustine (BiCNU®), Etoposide, 
cytarabine (AraC) and Melphalan – combined with mobilising procedures that include cyclophosphamide (Cy) and G-
CSF, CD34+ selection and ATG in vivo purging. The cytotoxic agents involved carry significant potential side effects, 
and immunoablation naturally also carries significant risks: hence the need seriously to consider the adverse effect 
profile of AHSCT. 
Myeloablative transplant regimens (such as total body irradiation (TBI) or full-dose busulfan) cause irreversible bone 
marrow failure, thus absolutely requiring haematopoietic stem cell re-infusion to regenerate bone marrow function. 
Toxicity and late complications can be substantial with myeloablative regimens (70), as demonstrated in Table 1. TBI 
is associated with a higher mortality. It has also been speculated that TBI may induce an endogenous factor that enhances 
demyelination or interferes with ongoing remyelination (24). The disadvantage of adding Cy to G-CSF is the increased 
risk to the patient due to an additional pancytopenic interval, increased cost of management of patients receiving 
chemotherapy, and the delay in proceeding to high dose immunosuppressive therapy (68). Fassas et al’s study (4) had 
a high mortality, but did valuably demonstrate that there was no evidence that more intense conditioning, purging or 
ATG use was associated with higher probabilities of confirmed progression-free survival (4).  
The most frequent adverse event noted in AHSCT was febrile neutropenia. There is also a high incidence of urinary 
tract infection, which is to be expected in patients with MS, who often already have neurological problems of bladder 
dysfunction, particularly in the progressive phase of the disease. The increased risk of infections in patients with reduced 
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mobility, together with restrictive pulmonary defects, supports the current suggestion of including patients with lower 
EDSS scores (22). The most frequent late adverse events reported in MS patients undergoing HSCT are varicella-zoster 
virus and herpes simplex virus reactivation, followed by the development of autoimmune diseases, including 
autoimmune thyroiditis (22).  
Transplant-related mortality (TRM) is plainly the greatest concern: any risk might be considered too high in relation to 
a condition – MS – which is not life-threatening per se (77). One retrospective survey looked at 183 patients with MS 
in the database of the EBMT Registry (19). The overall TRM was 5.3%, but importantly this mortality was noted only 
in the period of 1995-2000, with an apparent 0% TRM reported subsequent to 2000. Also, no deaths were noted in those 
treated with BEAM without graft manipulation. Improvement or stabilisation of neurological condition was noted in 
63% of patients, at a median follow-up of 41.7 months, and was irrespective of the conditioning regime. The analysis 
also suggested that in those using a moderate conditioning regime, a durable benefit was seen in some patients, quoting 
figures post-HSCT of up-to nine years (19). These observations provided further impetus for exploring alternative 
approaches to conditioning, although it should also be stressed that better patient selection criteria, and better supportive 
care, including infection prophylaxis are also likely to have contributed to the more recent reduction in TRM. 
Hamerschlak et al’s study is the only trial that has directly compared the toxicity of different conditioning regimes (78) 
– BEAM/ATG (horse) against the Cy/ATG (rabbit) regimen. The overall complication rate in the BEAM/ATG group 
was 71.4% - considerably higher than the Cy/ATG group figure of 40%. Three subjects (7.5%) died (of cardiac toxicity, 
sepsis and alveolar haemorrhage), all of them in the BEAM/ATG group. Moreover (and as with the retrospective EBMT 
Registry survey), the efficacy results were broadly similar, although the period of follow-up was relatively short (78).  
 
Cost-benefit and risk benefit 
Measurement of long term benefit in MS clinical trials has long been recognised to be extremely challenging. 
Determination of the risk-benefit ratio is also difficult, especially for patients with early MS, with mild to moderate 
disability and low EDSS scores, since the prognosis for long term survival is good, despite worsening physical ability 
(79). Six years ago, and in the most optimistic scenario, the cost-effectiveness of AHSCT was considered to be around 
£2800 per additional quality-adjusted life year (QALY) gained (5). The initial costs of HSCT are extremely high; and 
for any new and costly treatments to be applied widely in a resource-constrained health service, such as the National 
Health Service in the U.K., and many other health services, it is necessary to demonstrate value for money in the context 
of other competing priorities (5). At present, there have been no phase III prospective randomised studies that compare 
the efficacy of AHSCT against other conventional therapies. The only comparative trial is the Autologous 
Haematopoietic Stem Cell Transplantation trial in MS (ASTIMS), a phase II study that was designed to assess the effect 
of AHSCT vs. mitoxantrone (MTX) on disease activity in MS, measured by MRI in the 4 years following treatment 
(80). The results of this trial are summarised in table 1. In terms of cost-effectiveness and benefit of AHSCT, considering 
a 6-month sustained progression rule, the study demonstrated that AHSCT is less effective than mitoxantrone, using a 
decision-analytic Markov model for evaluation (80). Mitoxantrone is little used now in MS, diminishing the practical 
value of this study. 
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To assess the risk-benefit ratio of HSCT in MS, Daumer et al investigated the natural history of moderately severe MS, 
and concluded that the probability of reaching an EDSS score of 10 (death), after 15 years was 22%. In Fassas et al’s 
study, exploring the long term outcome of HSCT, the combined disease-related mortality and procedure-related 
mortality was 17%, thus at face value comparatively favourable (73, 79). In Daumer et al’s study, the risk for progression 
to advanced disability, defined as an EDSS score of 8, was very low for the subgroup with a baseline EDSS score of 3-
3.5; however, for those with a baseline EDSS score of 4-5.5, 3% had advanced disability after two years, 5% after three 
years, 6% after four years, 12% after five years, and 40% after 10 years (79). In light of this, the progress-free survival 
rates of AHSCT trials might be seen as favourable, although there is little evidence from long term follow-up studies. 
 
In summary, there are clearly still significant gaps in the evidence, and the next steps would involve exploring phase III 
randomised trials, with larger recruitment of patients and longer follow-up, and in particular with comparison against 
current licensed more potent treatments, including natalizumab and alemtuzumab, to elicit the true efficacy of cell 
therapy, and to assess the cost-effectiveness and risk versus benefit quotient in these patients. Only one trial with 
considerable follow-up of 11.3 years commented that disease progression (with or without initial improvement post 
HSCT) still occurred in a significant proportion of their patients despite impressive sustained effect in suppressing 
activity on MRI, suggesting that HSCT is not a therapy for the progressive population of MS, and should be reserved 
for those with aggressive relapsing disease, in the inflammatory phase and for the malignant form of MS (67, 73).  
 
 
 
Conclusion and future considerations 
Considerable advances in our understanding of MS physiology have allowed a paradigm shift in the management of MS 
from one that simply targets CNS inflammation towards one that at least aims to be both immunomodulatory and 
neuroprotective, and which additionally carries the potential for regenerative repair. Cell therapies intended to achieve 
repair by direct cell replacement have made limited progress towards clinical application, largely because of questions 
concerning the basis of this approach; however, related studies of the cellular biology of remyelination have yielded a 
number of molecular candidates for more conventional pharmacological approaches to myelin repair. 
Concerning HSCT, better outcomes are evident in patients with active inflammatory disease, shorter disease duration, 
and lower EDSS scores; and in those with RRMS rather than SPMS and PPMS. This is consistent with a treatment 
targeting control of peripheral immunity rather than directly affecting pathological processes within the CNS (22).  The 
increasing experience of neurologists and haematologists with conditioning regimes, with myeloablative versus non-
myeloablative treatment protocols, and in the management of adverse effects, has led to significant reductions in TRM. 
While the precise place of HSCT in the overall treatment paradigm for MS remains to be defined, it is increasingly no 
longer seen as a last resort for patients with a poor prognosis (22).  
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Recent trials are exploiting the immunomodulatory, neuroprotective and reparative properties of other bone marrow-
derived stem cells, such as MSCs, and of comparable cells from other sources. These approaches carry a number of 
practical advantages, including relative ease of access and safety of administration, as well as avoiding the need for 
immunosuppressive treatment to prevent rejection (41). Thus far, published trials have been limited to small safety and 
feasibility studies, and while these have shown a favourable adverse event profile, the efficacy of MSC transplantation 
has been modest. The same applies to trials that have explored the avenue of non-selected, non-expanded cells. Phase 
II/III trials of both approaches are now underway (57, 61, 81). With regards to other cell types, such as human placental-
derived stem cells, there is a considerably greater sparsity of trial evidence (59). 
In an era where cell therapy has been rapidly expanding in other fields such as cardiovascular medicine, and with the 
limited options of conventional treatments available for progressive MS, there is a drive to accelerate trials in MS to 
explore the efficacy and cost-effectiveness of cell therapy. However, it is only by recruiting patients to carefully designed 
clinical trials and populating detailed registries, that we will acquire data to enable us to answer the question of whether 
cell therapy is truly beneficial to the general population of patients with MS. 
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Table 1: Overview of clinical trials of cell therapy in MS 
Part A: Summary of HSCT/BMT trials 
Author Time- 
frame 
Type of 
MS 
(number 
of 
patients 
or %) 
Age Follow-
up 
(years) 
mean/ 
median 
Treatment Outcomes  Adverse Events 
(number of patients 
or %) 
Fassas 
et al 
(73) 
1995-
2001 
SPMS 
(19) 
PRMS (4) 
RRMS 
(1) 
PPMS (1) 
Median 
= 40 
Range =  
9-54 
11.3  Cy+G-CSF, 
BEAM or 
busulfan 
+ATG, IV 
PBSC 
-EDSS improved 
26%  
-11.3 year PFS 25% 
-Gd+ lesions 
reduced from 
9.53cm3 to 0.17cm3 
-TRM (2) 
(aspergillosis and 
pulmonary 
haemorrhage) 
Nash et 
al (68) 
1998-
2001 
 PPMS 
(14) 
SPMS 
(17) 
RRMS 
(1) 
Median
= 41 
2 Cy+G-CSF, 
TBI+ATG, 
IV PBSC 
  
-Progression 
estimate 3 years  
27%  
-Gd+ lesion volume 
decrease- 6.6% (1 
year) 
-TRM (1)-EBV 
PTLD 
-Engraftment 
syndrome (13/18), 
MS flare (1), 
irreversible 
neurological 
deterioration (1), 
UTI (8), 
bacteraemia (4), 
central venous 
catheter infection 
(1), viral self-
limiting illness (7), 
ITP (1), brachial 
neuritis (1) 
Mancar
di et al 
(18) 
1998 SPMS 
(10) 
Median
= 35.5 
Range= 
26-52 
1.25 Cy+  
G-CSF, 
BEAM, IV 
PBSC  
 
-Gd+ suppression 
100% 
-EDSS 6.5 to 6.0 (6 
months)  
-No TRM 
-Febrile 
neutropenia (9), 
transient elevation 
of liver enzymes 
(2), rash (1), UTI 
(3), non- or 
symptomatic CMV 
reactivation (3), 
gastric pain (1), 
subclavian phlebitis 
(1), SIADH (1)   
Capello 
et al(82) 
1998 RRMS 
(4) 
SPMS 
(17) 
Median
=24 
2 Cy+G-CSF, 
BEAM 
+ATG, IV 
PBSC 
-EDSS stable or 
improved 95%  
 
Haemorrhagic 
cystitis (1), 
subclavian phlebitis 
(1), transient 
SIADH (1), CMV 
reactivation (6) 
Saccardi 
et al 
(83) 
1998-
2003 
SPMS 
(15) 
RRMS 
(4) 
Median 
=36 
Range= 
26-52 
3 Cy+G-CSF, 
BEAM, 
+ATG, IV 
PBSC 
-Gd+ suppression 
95% 
-6 year PFS 95% 
-4.5 year DFS 64%  
-No TRM 
-Fever (16), 
haemorrhagic 
cystitis (1), UTI 
(1), CVC-related 
phlebitis (1), 
inappropriate 
secretion of ADH 
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(1), sepsis (5), 
enteritis (1), 
transient elevation 
of LFTs (1), gastric 
ulcer bleeding (1), 
HZV infection (1), 
transient 
monoclonal 
gammopathy (1) 
Kozak 
et al 
(84) 
1998-
1999 
SPMS 
(11) 
Range 
=25-44 
0.71 Cy+G-CSF, 
BEAM+/-
ATG, IV 
PBSC 
-EDSS 
improvement 77%, 
-Gd+ suppression 
55% 
-No TRM 
Febrile neutropenia 
(all), Gram + 
bacteraemia (2), 
arm cellulitis (1), 
herpes zoster (1) 
Fassas 
et al (4) 
1999-
2000 
PPMS 
(26%) 
SPMS 
(70%) 
RRMS 
(4%) 
Median
=39  
Range= 
20-58 
1.3 Cy +/-  
G-CSF, 
BEAM, Cy 
+/-ATG or 
TBI and 
busulphan, 
IV PBSC 
and BM 
-EDSS 
improvement by ≥1 
in 21% at 3 years 
-PFS 74% 
-Disease 
progression in 20% 
-Gd+ lesions in 
33% pre- to 8% 
post-transplant 
-TRM – 7 patients 
(5 cytotoxicity, 2 
neurological 
complication) 
-Neurological 
deterioration 
(27%), 
infection/allergic 
events/severe G-
CSF induced bone 
pain (15%), 
infection/cardiac 
and hepatic 
toxicity, bleeding, 
TTP (59%) 
Shevche
nko et al 
(16) 
1999-
2006 
SPMS 
(27) 
PRMS (1) 
PPMS 
(11) 
RRMS 
(11) 
Median
= 32  
Range  
=18-51 
1.6 Cy +  
G-CSF 
BEAM+ 
ATG, IV 
PBSC 
 
-EDSS score of 0.5- 
62.5% at 1.6 years  
-Gd+ lesions 
suppressed 43.3% 
-6 year PFS 72% 
-No TRM 
-Neutropenic fever 
(51.6%), hepatic 
toxicity (48.1%), 
transient 
neurological 
dysfunction 
(22.2%), 
enteropathy 
(18.5%), sepsis 
(2%) 
Krasulo
va et al 
(76) 
1999-
2008 
RRMS 
(11) 
SPMS 
(15) 
Median
=33 
5.5 Cy+G-CSF, 
BEAM+ 
T-cell 
depletion, 
IV PBSC  
-PFS estimate 
70.8% at 3 years, 
29.2% at 6 years  
-No TRM 
-Febrile 
neutropenia (14), 
sepsis (11), UTI 
(7), diarrhoea (16), 
mucositis (11), 
arthralgia (1), 
HSV1 and VZV 
(1), chronic hep B 
(1), GBM (1), 
Acquired anti-
factor VIII inhibitor 
(1) 
Ni et 
al(69) 
2000-
2005 
 SPMS 
(16) 
PPMS (2) 
Median
= 37 
3.5 Cy+G-CSF, 
TBI or 
BEAM 
-3.5 year PFS 75% 
-3.5 year DFS 
33.3%  
-TRM (2)- severe 
pneumonia and 
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PRMS (2) 
Malignant 
MS (1) 
Range= 
15-58 
+ATG, IV 
PBSC  
 
-Gd+ lesions post-
transplant 14.3%  
varicella-zoster 
virus hepatitis 
-Allergy 
(4),infection (8), 
elevation of liver 
enzymes (6), 
transient 
neurological 
deterioration (5), 
depression (5) 
Chen et 
al (14) 
2000-
2007 
SPMS 
(19) 
PPMS (1) 
RRMS(3) 
PRMS (2) 
Median 
= 37.3 
Range = 
15-64 
4.9 Cy+G-CSF,  
BEAM+ 
ATG, IV 
autologous 
PBSC  
-EDSS 8.0 to 5.5-
7.0 (1 year) 
-3 year PFS = 74% 
-Gd+ lesions 
suppressed/nil new  
58% 
 
-TRM (2)- 
Pneumonia (1) 
Varicella-zoster 
virus hepatitis (1) 
-Bacterial infection 
(13) 
Opensha
w et al 
(24) 
2000 SPMS (5) Range = 
39-47 
2 G-CSF, 
Busulfan+ 
Cy+ATG, 
IV PBSC 
-2 year EDSS 
improvement 50%, 
- Gd+ suppression 
100% 
-TRM (1)- 
influenza A 
pneumonia 
-Line infection (1), 
C.diff diarrhoea (1), 
severe MS flare (1) 
-NTRM- 
S.pneumonia sepsis 
Hamers
chlak et 
al (78) 
2001-
2006 
PPMS (4) 
SPMS 
(33) 
RRMS 
(4) 
Mean = 
42  
Range = 
27-53 
1.5 Cy+G-CSF 
then 
BEAM/ 
ATG 
(horse) or 
CY/ATG 
(rabbit), IV 
PBSC 
-EDSS improved 
63.2%  
(no difference 
between two 
regimes)  
-No new Gd+ 
lesions  
-TRM 3 in 
BEAM/ATG group 
(cardiac 
toxicity/sepsis/alve
olar haemorrhage) 
-Febrile 
neutropenia (18), 
pneumonia (8), 
allergy to ATG (5), 
UTI (7), DVT and 
PE (3), depression 
(3)  
Atkins 
et al 
(71) 
2001-
2009 
RRMS 
(12) 
SPMS 
(12) 
Median 
=34  
Range=
24-45 
6.7  Cy+G-CSF, 
Busulfan, 
Cy+ATG, 
IV PBSC 
-3 year DFS 69.6% 
-No new Gd+ 
lesions  
-TRM – hepatic 
necrosis (1) 
-UTI (13%), ITU 
admission (sinusoid 
obstruction 
syndrome), febrile 
neutropenia (all), 
positive cultures 
(29), viral 
infections (26%), 
thyroid dysfunction 
(5), immune 
thrombocytopenia 
(1)  
Burt et 
al (85) 
2003 RRMS 
(21) 
Range = 
21-52 
 
2.6   G-CSF+Cy, 
IV PBSC 
-EDSS ≤6.0 stable 
43%  
-Gd+ suppression 
57% 
-TRM (2),  
-Pseudomonas 
bacteraemia (1), 
dermatomal zoster 
(2), disseminated 
zoster (1),  
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rash/fever/fatigue 
(5) 
Burt et 
al (75) 
2003-
2005 
RRMS 
(21) 
Range 
=20-53 
Median 
=33 
3.1 Cy+G-CSF, 
Cy+ 
Alemtumuz
ab/ATG, 
IV PBSC 
-EDSS 
improvement 1 
point 81% 
-3 year RFS 76%  
-3 year DFS 62% 
-No TRM 
-C.diff diarrhoea 
(1), dermatomal 
zoster (2), ITP (2), 
neutropenic fever 
(5),  transient 
neurological 
hypoaesthesia (1) 
Burt et 
al (70) 
2003-
2014 
RRMS 
(123) 
SPMS 
(28) 
Mean = 
36 
Range = 
18-60 
2.5  Cy+G-CSF, 
alemtuzum
ab 
/ATG, IV 
autologous 
PBSC 
 
-EDSS 4.0 to 2.5  
(4 years) 
-4 year RFS = 80%  
-4 year PFS= 87%.  
-T2 lesion volume 
8.57cm3 to 5.74cm3 
(27months) 
-No TRM 
-Dermatomal zoster 
(4), ITP (7), 
hypothyroidism (7)  
Saiz et 
al (86) 
2004 SPMS (9) 
RRMS 
(5) 
Median
= 30 
Range= 
22-45 
3  Cy + 
G-CSF, 
BEAM+ 
ATG, IV 
PBSC 
-3 year PFS 85.7% 
-3 year DFS 46.4% 
-No new T1 lesions 
-50% reduction in 
T2 lesion volume 
-No TRM 
-Neurological 
deterioration (3), 
secondary 
amenorrhea (4) 
Fagius 
et al(67) 
2004 RRMS 
(9) 
Median 
=  
27 
Range=  
9-34 
2.4 Cy+G-CSF, 
BEAM+ 
ATG, IV 
PBSC  
-EDSS 
improvement 3.5  
-No new T2 lesions 
-No TRM 
-Crohn’s disease 
(1) 
-Mucositis, 
alopecia, sepsis (2), 
serum sickness (2), 
herpes zoster (1) 
Mancar
di et al 
(80) 
2004-
2009 
SPMS (6) 
RRMS 
(7)  
PRMS (8)  
Mean 
=36, 
Range = 
22-46 
4 Cy +  
G-CSF, 
BEAM+ 
ATG and 
IV PBSC, 
compared 
with 
mitoxantro
ne (MTX) 
-AHSCT reduced 
number of T2 
lesions by 79% 
compared to MTX. 
-No difference 
noted in the 
progression of 
disability 
-No TRM 
-Febrile 
neutropenia/diarrho
ea/leukopenia/muc
ositis/anaemia/ame
norrhea, reduced 
platelet count 
(80%)  
-Prolonged 
hospitalisation with 
late engraftment 
(1), systemic 
candidiasis and 
CMV reaction (1), 
ATG reaction (1) 
Bowen 
et al 
(87) 
2005-
2008 
SPMS 
(17) 
PPMS (8) 
RRMS 
(1) 
Median 
= 41 
Range = 
27-60 
4 TBI, Cy + 
ATG, IV  
PBSC  
-EDSS improved 
15%  
-3 year PFS 63% 
-6 year PFS 48% 
-T2 lesion volume 
decrease 12.3% (3 
years) 
-TRM- EBV PTLD 
(1) 
-NTRM (4) 
-Myelodysplastic 
syndrome (post 7 
years- Tx with 
mitoxantrone) 
Shevche
nko et al 
(88) 
2005-
2011 
RRMS 
(43) 
SPMS 
(56) 
Mean = 
35 
4 BEAM-like 
conditionin
g, G-CSF, 
IV PBSC 
-8 year disease 
progression 16.7%  
-Event free survival 
80%  
No TRM 
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Shevche
nko et al 
(23) 
2006-
2011 
SPMS 
(35) 
PPMS 
(15) 
PRMS (3) 
RRMS 
(42) 
Not 
given 
3.8 G-CSF, 
BCNU/ 
CCNU and 
melphalan/ 
mini-
BEAM 
like+ ATG, 
IV PBSC  
-EDSS 
improvement or 
stabilisation 80% 
-5 year PFS 92% 
(early AHSCT), 
73% for 
conventional 
salvage AHSCT  
-No TRM 
-Thrombocytopenia 
(100%), 
neutropenia 
(100%), fatigue 
(100%), anaemia 
80%), alopecia 
(80%), hepatic 
toxicity (42.1%), 
transient 
neurological 
decline (27.4%), 
enteropathy (7.4%), 
skin allergy (8.4%), 
pneumonia (2.1%), 
uterine bleeding 
(2.1%), oral herpes 
(1.05%), genital, 
herpes (1.05%), 
sepsis (3.2%) 
Xu et al 
(89) 
2001-
2006 
SPMS 
(22) 
Median
=35.5 
Range= 
20-51 
3.25 G-CSF, 
BEAM, IV 
PBSC  
-3.25 year PFS 77% 
-59% of patients 
had neurological 
improvement  
-No TRM 
-Diarrhoea (13),  
fever (6), transient 
neurological 
decline (8), 
bacterial infection 
(7) 
Samijn 
et al 
(90) 
2006 SPMS 
(14) 
Median
=35  
Range= 
23-50 
3 Cy, 
TBI+ATG, 
IV BMSC 
-EDSS improved 
14%  
-3 year PFS 36% 
-No new Gd+ 
lesions  
-No TRM 
-Mucositis (10), 
rash (6), alopecia 
(all), fatigue (all), 
C.diff diarrhoea (2), 
fever (all), EBV 
PTLD (1), anti-
thyroid antibodies 
(3), 
myelodysplastic 
syndrome (1), 
herpes zoster (1), 
neurological 
deterioration (2), 
muscle spasms (2), 
loss of visual acuity 
(3)  
Rocca et 
al (28) 
2007 SPMS 
(14) 
Mean = 
38 
Range = 
23-50 
3  ATG+Cy, 
TBI, IV 
PBSC 
-Gd+ suppression -
100%  
-Stabilisation or 
improvement in 
EDSS in 35.7%  
-No TRM 
-EBV PTLD (1), 
anti-thyroid 
antibodies (3), 
myelodysplastic 
syndrome (1) 
Burman 
et al 
(72)  
2014 RRMS 
(40) 
SPMS (5) 
PPMS (5) 
Mean 
=31 
Range= 
9-52 
3.9 Cy + 
GC-CSF, 
BEAM+ 
ATG or 
Cy/ATG, 
IV PBSC 
-5 year relapse free 
survival 87%  
-MRI event-free 
survival 85% 
-5 year PFS 77% 
-5 year DFS 68%. 
-No TRM 
-Herpes zoster 
reactivation (15%), 
thyroid disease 
(8.4%), neutropenia 
fever (17), invasive 
fungal infection (1), 
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Crohn’s disease (1), 
alopecia areata (1), 
epilepsy (1) 
 
 
Part B: Summary of MSC/related trials 
Author Time- 
frame 
Type of 
MS 
(number 
of 
patients 
or %) 
Age Follow-
up 
(years) 
mean/ 
median 
Treatment Outcomes  Adverse Events 
(number of patients 
or %) 
Rice et 
al (60) 
2007-
2009 
RPMS (6) Mean = 
47.7 
1 IV BMSC  
 
-Multi-modal 
evoked potentials 
showed significant 
neurophysiological 
improvement 
Transient increase 
in lower limb 
spasticity (2), 
urinary retention 
(1) 
Connick 
et al (7) 
2007-
2010 
SPMS 
(10) 
Mean = 
48.8, 
Range = 
40-53 
18 
months  
IV (BM) 
autologous 
MSC  
-Improvement in 
visual acuity and 
visual evoked 
response latency 
-Increase in optic 
nerve area  
Rash following 
infusion (all),  
Bacterial infection 
(2) 
Llufriu 
et al(91) 
2010-
2012 
RRMS 
(5) 
Median 
age = 41 
Range= 
23-48 
1 IV (BM) 
autologous 
MSCs  
 
-Gd+ lesions at 6 
reduced (12.3 to 
3.1)  
 
Upper respiratory 
infection (1), 
influenza (1), 
gastroenteritis (1), 
herpes labialis (1) 
Karussis 
et al 
(41) 
2010 SPMS 
(17) 
PPMS (8) 
RRMS 
(1) 
Mean = 
35.3 
Range = 
27-60 
2.1 IT (BM) 
autologous 
MSCs 
-EDSS 6.7 to 5.9 
-No new Gd+ 
lesions at 6 months  
-No TRM 
-Transient fever 
(21), headache 
(15), meningeal 
irritation and 
aseptic meningitis 
(1) 
Yamout 
et al 
(56) 
2010 SPMS (9) 
RRMS 
(1) 
Range 
=34-56 
1 IT (BM) 
autologous 
MSCs 
-Vision and low 
contrast sensitivity 
at 3 months 
improved in 83% 
Transient 
encephalopathy (1), 
cervical and back 
pain (1) 
Bonab 
et al(92) 
2008-
2010 
SPMS 
(23) 
PRMS (2) 
Mean=  
34.7 
1 IT (BM) 
autologous 
MSCs  
-EDSS 6.1 to 6.3 (1 
year).  
-72.8% EDSS 
stable  
- Gd+ lesions post-
transplant 25% 
-No TRM 
-Low-grade fever 
(all), nausea-
vomiting (2), 
weakness in lower 
limbs (2) and 
headache (3) 
Lublin 
et al 
(59) 
2010-
2011 
RRMS 
(10) 
SPMS (6)  
Low 
dose 
median 
52.5, 
high 
dose 
median 
47.5 
1  IV Human 
placenta 
tissue (non-
autologous)
, PDA-001 
(mesenchy
mal-like 
stem cells) 
 
-Stable or decrease 
in EDSS 94% 
-No TRM 
-MS flare (6%), 
anaphylactoid 
reaction (6%), 
superficial 
thrombophlebitis 
(6%), headache 
(44%), URTI 
(31%), fatigue 
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(25%), infusion site 
reactions/events (4) 
and UTI (25%) 
Li et al 
(93) 
2010-
2012 
23 
(RRMS+
SPMS), 
10 given 
placebo  
Mean= 
41.7 
1 IV non-
autologous 
Human 
umbilical 
cord-
derived 
MSCs  
-EDSS score and 
relapse recurrence 
significantly lower 
than the control 
group 
None reported 
Cohen 
et al(94) 
2014 RRMS 
(10) 
SPMS 
(14) 
Mean = 
46.5 
0.5 IV 
autologous 
MSCs with 
human 
fibroblast 
growth 
factor 2 
-No significant 
improvement noted  
No serious AE 
reported  
 
PBSC=peripheral blood stem cells, BMSC=bone-marrow derived stem cells, BM=bone marrow, TRM= treatment 
related mortality, PFS=progressive free survival, RFS= relapse free survival, DFS=disease activity free survival, 
MSC=mesenchymal stromal cells, Gd+=Gadolinium enhancing MRI lesions, Cy=cyclophosphamide, G-
CSF=granulocyte colony stimulating factor, BEAM=carmustine, etoposide, cytosine-arabinoside, melphalan, TBI=total 
body irradiation, ATG=anti-thymocyte globulin, IT=intrathecal, IV=intravenous, EBV PTLD=Epstein Barr Virus Post-
Transplant Lymphoproliferative Disorder, Tx=treatment. Unless otherwise stated, clinical outcome data is stated for the 
end of the follow-up period.  
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